Certain medications may require predefined criteria before being approved for coverage. Other drugs may have daily or monthly limits recommended by the Food and Drug Administration, the drugs manufacturer, and/or  peer-reviewed medical literature. These instances may require a doctors request for preapproval or prior authorization.

 

The following guidelines, developed by Blue Cross and Blue Shield of Alabama's Pharmacy and Therapeutics Committee, are meant to help members understand the requirements related to their pharmacy coverage. Healthcare providers should use their best medical judgment in providing the care they feel is most appropriate for their patients.

 

Please note: Some employer groups may have specific drug coverage requirements for their employees that are not included in the criteria below.

Search by Drug Name

Product Name Implementation Date Guideline
ATACAND HCT® 01/01/11 Atacand HCT may be subject to step therapy requirements. Patients must have trial and failure of both of the following: 1) generic ACE inhibitor or generic ARB, AND 2) preferred brand ARB (Diovan, Exforge/HCT, Micardis/HCT).
ATACAND® 01/01/11 Atacand may be subject to step therapy requirements. Patients must have trial and failure of both of the following: 1) generic ACE inhibitor or generic ARB, AND 2) preferred brand ARB (Diovan, Exforge/HCT, Micardis/HCT).
ATELVIA™ 04/01/11 The limits are 4 tablets per 30 days.
ATRALIN® 04/01/01 Prior authorization for medical necessity may be required.
ATRIPLA 07/01/12 The limits are 1 tablet per day.
ATROVENT HFA 04/01/12 The limits are 2 inhalers per 30 days.
ATROVENT NASAL INHALER 07/01/13 The limits are 60 mL per 30 days for 21 mcg/spray and 45 mL per 30 days for 42 mcg/spray.
AUBAGIO® 01/01/13 Aubagio may be subject to step therapy. Patients must have trial and failure of two of the four preferred products: Betaseron, Copaxone, Rebif, or Tecfidera. The limits are 1 tablet per day.
AVALIDE® 01/01/11 Avalide may be subject to step therapy requirements. Patients must have trial and failure of both of the following: 1) generic ACE inhibitor or generic ARB, AND 2) preferred brand ARB (Diovan, Exforge/HCT, Micardis/HCT).
AVANDAMET® 08/06/08 The limits are 2 tablets per day.
AVANDARYL® 07/01/10 The limits are 1 tablet per day.
AVANDIA® 07/01/10 Avandia 2mg and 4mg has a limit of 2 tablets per day. Avandia 8mg has a limit of 1 tablet per day.
AVAPRO® 01/01/11 Avapro may be subject to step therapy requirements. Patients must have trial and failure of both of the following: 1) generic ACE inhibitor or generic ARB, AND 2) preferred brand ARB (Diovan, Exforge/HCT, Micardis/HCT).
AVIDOXY™ DK 04/01/13 Avidoxy DK may be subject to step therapy requirements. Patients must have trial and failure of generic immediate release doxycycline.
AVINZA® 05/15/09 The limits are 1 capsule per day.

Healthcare Reform

Questions about
Healthcare Reform?
Learn More

HealthQuotient®

What's your HQ Score? Get Started Now!